Health Funding Opportunities

blog navigation

Health Funding Opportunities

This is a collection of select grant funding opportunities available in the health sciences. This information is collected from a variety of sources including the Office for the Vice Chancellor for Research, Foundation Relations, and the Office for Proposal Development.

blog posts

  • Clinical Research Sites for the Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT sites) (U24)

    The purpose of this FOA, issued by NINDS, is to invite currently awarded NeuroNEXT sites and potential new sites to participate as a Clinical Site in the Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT). This clinical research network develops and conducts multiple, scientifically sound, possibly biomarker-informed exploratory clinical trials evaluating the most promising therapies for neurological disorders, whether from academic, foundation or industry discoveries. Examples include Phase 2 clinical trials and clinical research studies aimed at validating biomarkers and clinical outcomes in preparation for clinical trials. The network provides a robust, standardized, and accessible infrastructure to facilitate rapid development and implementation of protocols in neurological disorders affecting adult and/or pediatric populations. While the network is not specific to one disease, it has the capacity to coordinate a cadre of specialist investigators to implement studies efficiently in response to disease-specific opportunities. This FOA solicits applications for Clinical Sites. Separate FOAs solicit applications for the Clinical Coordinating Center and the Data Coordinating Center. The PD/PI must be a clinical trials expert with neurology trial expertise and a track record in successfully implementing clinical trials. 

    Amount: The maximum allowable direct cost per year for a NIH NeuroNEXT site will be $200,000

    Letter of Intent Deadline: New Date - August 26, 2017

    Application Deadline: New Date - September 26, 2017


  • DoD Epilepsy Research Program Awards

    The U.S. Department of Defense is seeking applications for the following FY17 Epilepsy Research Program Awards:

    - Epilepsy Risk Factors Award RFP

    - Idea Development Award RFP

    Letter of Intent Deadline (for both awards): September 6, 2017

    Application Deadline (for both awards): September 20, 2017

    For more information regarding these awards, please click here.

  • Central Neural Mechanisms of Age-Related Hearing Loss (R01)

    The purpose of this FOA, issued by NIA and NIDCD, is to encourage basic or clinical research applications that investigate central neural mechanisms of age-related hearing loss in older adults and/or in relevant animal models. This FOA is driven by the need to address a major gap in our understanding of the central pathways and neural networks that are involved in hearing loss and how these may be altered in the context of the aging brain, as well as how natural aging influences central auditory plasticity.

    Amount: Application budgets are limited to $500,000 in direct costs per year

    Letter of Intent Deadline: October 8, 2017

    Application Deadline: November 8, 2017


  • First in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Devices for Psychiatric Disorders (U01)

    The purpose of this FOA, issued by NIMH, is to encourage cooperative agreement applications to support early stage clinical trials of novel mechanism of action, investigational drugs or drug candidates for the treatment of psychiatric disorders in areas of unmet medical need. The FOA will support milestone-driven early stage trials in pediatric and adult populations. First in human (FIH) and Phase Ib studies of novel Agents must assess target engagement (brain exposure), pharmacological effects, safety, and tolerability to assess feasibility for Phase II/proof of concept (PoC) studies in psychiatric disorders. PoC studies must evaluate the drug’s impact on clinically relevant physiological systems (functional measures) and clinical indicators of effect. The FOA also supports FIH and early feasibility studies (EFS) of novel devices to evaluate target engagement, safety, tolerability, and efficacy. The overall objective is to facilitate rapid collection of data to "de-risk" novel mechanism of action investigational drugs, novel drugs for use in pediatric populations with psychiatric disorders, and devices or combination treatments in order to attract private funding for further clinical development as FDA-approved treatments. A key aspect of this FOA is the formation of collaborative partnerships between the biomedical researchers and biotechnology or industry researchers to facilitate psychiatric drug or device development.

    For pediatric drug trials, the application must include the joint participation of a pediatric pharmacologist and pediatric psychiatrist, as multiple PIs. Additionally, it is required that Contract Research Organizations (CROs) or CTSAs, with expertise in first in pediatric PK/PD bridging studies, will conduct the trial(s). Additionally, for all other trials that fit the goals of this FOA, it is required that CROs or CTSAs with expertise in the age range and intervention type, conduct the trials.

    Amount: Application budgets are not limited but need to reflect the actual needs of the proposed project

    Letter of Intent Deadline: 30 days prior to the application deadline

    Application Deadline: October 5, 2017


  • Alzheimer’s Drug Discovery Biomarker Studies Program

    Clinical trials for Alzheimer's disease and related dementias have been hindered, in part, by the limited number of biomarkers available to (1) accurately diagnose these diseases, (2) enrich and stratify patient cohorts, (3) demonstrate target engagement for novel therapeutics, and (4) reliably monitor disease progression and response to treatment. While currently available biomarkers have helped to accelerate clinical trials, most are either expensive, invasive, or both, and provide information on a small number of disease targets. Thus, additional biomarkers are needed to provide a more complete picture of the disease. To that end, the Alzheimer's Drug Discovery Foundation has issued a Request for Proposals to support the development and validation of biomarkers that will enhance the design and performance of clinical trials for Alzheimer's disease, related dementias, and cognitive aging.

    Grants of up to $300,000 over two years will be awarded in support of projects related to the development of biomarkers previously identified in samples from well-characterized human subjects. Validated methods should be used in quantifying and qualifying biomarkers, and the organization will give lower priority to the development of novel technologies. Priority biomarker areas include companion biomarkers, neuroimaging, CSF and blood-based biomarkers, and functional activity measures. Eligible applicants include academic investigators seeking to create and support innovative biomarker programs in academic medical centers and universities, and biotechnology companies with programs dedicated to Alzheimer's disease biomarker development. Funding is provided through mission-related investments that require return on investment based on scientific and/or business milestones.

    Amount: Up to $300,000/year for up to 2 years

    Letter of Intent Deadline: July 31, 2017


  • CIGNA Foundation Grants in Community Health Navigation

    The Cigna Foundation is deeply committed to providing opportunities for individuals everywhere to achieve the best possible health. The Foundation pursues this goal through providing World of Difference Grants that focus on Health Equity, helping people overcome barriers to their health and well-being related to factors such as ethnicity, race, gender, age, geography, or economics.

    World of Difference Grants emphasize partnership: sharing the knowledge and expertise of Cigna's professionals with dedicated non-profit partners. Individuals can’t achieve their best possible health if they don’t understand the health challenges they face. They can’t access community health resources if they don’t know they exist. The solution to both dilemmas is Community Health Navigation—projects and programs aimed at connecting individuals and better health through the efforts of trusted neighbors and organizations. A well-designed Community Health Navigation program can be a powerful tool in bringing improved Health Equity to underserved populations. Community Health Navigation can take many forms. Often it starts with faith-based organizations. In other cases, neighborhood clinics or emergency medical workers may play a role.

    Amount: Up to $200,000

    Deadline: Applications accepted on a rolling basis


  • BRAIN Initiative: New Concepts and Early - Stage Research for Large - Scale Recording and Modulation in the Nervous System (R21)

    This FOA seeks applications for unique and innovative technologies that are in an even earlier stage of development than that sought in other FOAs, including new and untested ideas that are in the initial stages of conceptualization. In addition to experimental approaches, the support provided under this FOA might enable calculations, simulations, computational models, or other mathematical techniques for demonstrating that the signal sources and/or measurement technologies are theoretically capable of meeting the demands of large-scale recording or manipulation of circuit activity in humans or in animal models. The support might also be used for building and testing phantoms, prototypes, in-vitro or other bench-top models in order to validate underlying theoretical assumptions in preparation for future FOAs aimed at testing in animal models. Invasive or non-invasive approaches are sought that will ultimately enable or reduce the current barriers to large-scale recording or manipulation of neural activity, and that would ultimately be compatible with experiments in humans or behaving animals. Applications are encouraged from any qualified individuals, including physicists, engineers, theoreticians, and scientists, especially those not typically involved with neuroscience research. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are encouraged to apply for support.

    Amount: The combined direct cost budget for the two-year project period may not exceed $300,000. No more than $200,000 may be requested in any single year

    Deadline: October 26, 2017


  • DoD Peer Reviewed Alzheimer's Research Program Awards

    The U.S. Department of Defense is seeking applications for the following FY17 Peer Reviewed Alzheimer's Research Program (PRARP) Awards:

    - Convergence Science Research Award RFP

    - New Investigator Research Award RFP

    - Research Partnership Award RFP

    - Quality of Life Research Award RFP

    Letter of Intent Deadline (for all awards): September 6, 2017

    Application Deadline (for all awards): September 20, 2017

    For more information regarding these awards, please click here.

  • Genetech Age-related Macular Degeration Research Fellowships

    The ARVO Foundation for Eye Research, the philanthropic arm of the Association of Research in Vision and Ophthalmology, was established in 2001 to ensure stable support for innovative and novel vision research, particularly work with translational impact that fosters collaboration between clinicians and basic scientists.

    The foundation is inviting applications for two Genentech Age-Related Macular Degeneration Research Fellowships in support of research related to age-related macular degeneration. A single grant of $40,000 grant will be awarded to a basic researcher working to advance the understanding of AMD, while a second grant of $40,000 will be awarded to an AMD researcher focused on therapeutics. To be eligible, applicants must be a newly established investigator age 45 or younger at the time of application. While ARVO membership is not necessary, applicants must currently be working in a nonprofit or academic research center.

    Amount: $40,000

    Deadline: September 1, 2017


  • Clinical Research Training Fellowship in Parkinson's Disease - Funded by Lundbeck

    The American Academy of Neurology (AAN) is pleased to support clinical research training in the neurosciences. This award aims to recognize the importance of good clinical research and to encourage young investigators in clinical studies. The AAN Research Program demonstrates the AAN Board of Directors dedication to promoting neurology and neuroscience research and training. Recipient must be an AAN member interested in an academic career in neurological research who has completed residency or a PhD no more than 5 years prior to the beginning of this award.

    Amount: $55,000 per year for two years, plus a $10,000 per year stipend to support education and research-related costs for a total of $130,000

    Deadline: October 1, 2017